Augmedix, Inc. (NASDAQ:AUGX) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET

Company Participants

Caroline Paul - Investor Relations

Manny Krakaris - Chief Executive Officer

Paul Ginocchio - Chief Financial Officer

Conference Call Participants

Ryan Daniels - William Blair

Marc Wiesenberger - B. Riley Securities

Allen Klee - Maxim Group

Brooks O'Neil - Lake Street Capital Markets

Operator

Hello, and welcome to the Augmedix, Inc. Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode [Operator Instructions]. As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host Caroline Paul, Investor Relations. Thank you. You may begin.

Caroline Paul

Thank you. And thank you all for participating in today’s call. Joining me are Manny Krakaris, Chief Executive Officer; and Paul Ginocchio, Chief Financial Officer. Earlier today, Augmedix released financial results for the quarter ended June 30, 2022. A copy of the press release is available on the company’s Web site.

Before we begin, I’d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance, are forward-looking statements.

These forward-looking statements are based upon our current estimates and various assumptions and involve material risks and uncertainties that could cause actual results or events to materially defer from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors and management discussion and analysis of financial condition and results of operations in our most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, and similar disclosures and subsequent reports filed with the SEC. This conference call contains time sensitive information and is accurate only as of the live broadcast today, August 08, 2022. Augmedix disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.

And with that, I’ll turn the call over to Manny.

Manny Krakaris

Thanks, Carolyn. Good afternoon, everyone, and thank you for joining us. Before we dive into second quarter results, I want to describe the problem we are addressing and what we are doing to help solve that problem. There are now numerous demands competing for a physician's attention at the point of care. Chief among those is electronic documentation. Too much of the patient visit is consumed by completing EHR checkboxes, entering orders, manually preparing prior authorization requests and managing inbox messages. The result is a virtual wall between the patient and the physician, which has led to a significant reduction in productivity for the industry and unprecedented levels of physician burnout and patient dissatisfaction. For those who are not familiar with our company, Augmedix is leading a fundamental shift at the point of care by automatically and accurately generating digital documentation of physician patient interactions unobtrusively, thereby reducing physician’s administrative burden and freeing them to practice at the top of their license.